

## **Notice of Ending Collaboration Agreement with Adaptimmune Limited**

Noile-Immune Biotech Inc. (hereinafter referred to as “Noile-Immune”) hereby announces that a collaboration agreement (hereinafter referred to as “Collaboration”) with Adaptimmune Limited (hereinafter referred to as “Adaptimmune”) has been ended.

Since August 2019, under the Collaboration, Adaptimmune has been applying Noile-Immune's proprietary PRIME technology to Adaptimmune's technology, and conducting research and development on TCR-T cell therapy technology. However, taking into consideration comprehensively the progress of the research and development activities, Adaptimmune's development capacity, and Noile-Immune's optimal allocation of business and development resources, etc., a discontinuation of the Collaboration has been decided by mutual confirmation between the two companies.

It should be added that the discontinuation of the Collaboration is not related to any concerns about the safety or efficacy of PRIME technology, but to the comprehensive decisions of both companies.

Noile-Immune is currently focusing on the development of its highest priority pipeline, NIB103, and will continue to demonstrate the efficacy of the PRIME technology by vigorously promoting in-house drug development.

Noile-Immune anticipates that the impact on its business performance for the fiscal year ending December 31, 2026 in relation to this matter is minor. However, should any matters arise that require disclosure, Noile-Immune will provide updates promptly.

### **Contact for inquiries or additional information**

2-12-10 Shiba-Daimon, Minato-ku, Tokyo 105-0012, Japan

Noile-Immune Biotech Inc.

[ir@noile-immune.com](mailto:ir@noile-immune.com)